Form 4: CG Oncology CFO James DeTore Receives Stock Options

CG Oncology CFO James DeTore was granted 90,574 employee stock options with an exercise price of $67.68.

Summary

• James DeTore, Chief Financial Officer of CG Oncology, Inc., was granted 90,574 employee stock options.
• The options have an exercise price of $67.68 per share.
• The grant date for these options is April 15, 2026.
• The options are set to expire on April 14, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative disclosure regarding executive compensation that does not signal a change in company fundamentals.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future shareholder dilution upon the exercise of these stock options.

Risks

• Market price volatility could impact the value of the options and the incentive structure for the executive.

Future Outlook

The options vest over a four-year period, with 25% vesting one year after the commencement date and the remainder in 36 equal monthly installments, indicating a long-term retention strategy.

Industry Context

StockSavvy.ai notes that equity grants for C-suite executives in the biotechnology sector are standard practice to ensure leadership retention and alignment with clinical and commercial milestones.

Comparison to Industry Standards

• The four-year vesting schedule is consistent with standard industry practices for executive compensation in mid-cap biotech firms.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of 25% of the options on April 15, 2027.
• Subsequent monthly vesting of the remaining 75% over the following three years.

Key Dates

Keywords

CG Oncology, CGON, Form 4, Insider Trading, Stock Options, Executive Compensation